RA Capital Healthcare Fund LP 4
4 · Vor Biopharma Inc. · Filed Apr 10, 2026
Research Summary
AI-generated summary of this filing
Vor Biopharma (VOR) 10% Owner RA Capital Sells Shares
What Happened
RA Capital Management, L.P. (a reported 10% owner and investment manager to RA Capital Healthcare Fund, L.P.) sold a total of 620,133 shares of Vor Biopharma (VOR) common stock in open-market/private sales between April 8 and April 10, 2026. The four reported transactions were:
- 353,242 shares at a weighted-average $16.32 — $5,764,909 (footnote: prices in this lot ranged $15.755–$16.68).
- 130,862 shares at a weighted-average $16.91 — $2,212,876 (footnote: range $16.755–$16.975).
- 135,201 shares at a weighted-average $16.59 — $2,242,985 (footnote: range $15.94–$16.385).
- 828 shares at a weighted-average $15.75 — $13,041 (footnote: range $15.75–$15.76).
Total proceeds reported across these sales: approximately $10.23 million. These were sales (not purchases), which are commonly portfolio or liquidity actions for institutional holders.
Key Details
- Transaction dates: Apr 8, 2026 (two blocks), Apr 9, 2026, and Apr 10, 2026. Weighted-average prices reported per block; footnotes indicate each block was executed in multiple trades across the stated price ranges.
- Shares sold: 620,133 total; total proceeds ≈ $10,233,811.
- Shares owned after transaction: not specified in the excerpt provided. The filing notes the sold shares were held directly by the Fund.
- Reporting structure/footnotes: RA Capital Management, L.P. is the Adviser to the Fund; RA Capital and related parties disclaim beneficial ownership except for pecuniary interest. The filing includes footnotes offering to provide breakdowns of the multiple execution prices on request.
- Board connection: Dr. Andrew Levin, a Partner/Managing Director of the Adviser, serves on Vor Biopharma’s board (disclosed in the filing).
- Filing timeliness: Form 4 was filed Apr 10, 2026 for trades Apr 8–10; no late filing is indicated in the report.
Context
- This is institutional/10%-owner selling, not necessarily an executive insider’s personal trade. Institutional sales can reflect portfolio rebalancing or liquidity needs and are not direct signals about company fundamentals.
- The filing reports weighted-average prices and provides price ranges per block (the reporting persons offer to provide per-trade price details on request).
- No option exercises, awards, gifts, or 10b5-1 plan disclosures are noted in the provided excerpt.
Insider Transaction Report
Form 4
RA CAPITAL MANAGEMENT, L.P.
Director10% Owner
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-04-08$16.32/sh−353,242$5,764,909→ 4,202,499 total(indirect: See footnotes) - Sale
Common Stock
[F4][F2][F3]2026-04-08$16.91/sh−130,862$2,212,876→ 4,071,637 total(indirect: See footnotes) - Sale
Common Stock
[F5][F2][F3]2026-04-09$16.59/sh−135,201$2,242,985→ 3,936,436 total(indirect: See footnotes) - Sale
Common Stock
[F6][F2][F3]2026-04-10$15.75/sh−828$13,041→ 3,935,608 total(indirect: See footnotes)
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.755 to $16.68 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- [F3]Held directly by the Fund.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $16.975 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.385 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $15.76 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.